Current Report Filing (8-k)
August 06 2020 - 6:57AM
Edgar (US Regulatory)
0000025743
false
0000025743
2020-08-06
2020-08-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE
ACT OF 1934
Date of Report
(Date of earliest event reported): August 6, 2020
(Exact Name of Registrant as Specified in its
Charter)
Nevada
|
|
001-00100
|
|
87-0233535
|
(State or Other
Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
951 Yamato Road, Suite 220
Boca Raton, FL 33431
|
(Address of Principal Executive Office) (Zip Code)
|
Registrant’s telephone number,
including area code: (561) 961-1900
Not Applicable
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of Each Class
|
Trading Symbol
|
Name of Each Exchange on Which Registered
|
Common Stock, par value $0.001 per share
|
TXMD
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230-405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item
2.02
|
Results
of Operations and Financial Condition.
|
On
August 6, 2020, TherapeuticsMD, Inc. (the "Company") issued a press release announcing its financial results for the
second quarter ended June 30, 2020. In addition, the Company will be using a slide presentation during its earnings conference
call. A copy of the press release and slide presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current
Report on Form 8-K and are incorporated herein by reference.
The
information in Item 2.02 of this Current Report on Form 8-K (including the exhibits) is furnished and shall not be deemed to be
“filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities of that section. The information in Item 2.02 of this Current Report on Form 8-K (including
the exhibits) shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities
Act”), or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation
language in the filing.
The
Company does not have, and expressly disclaims, any obligation to release publicly any updates or any changes in its expectations
or any change in events, conditions, or circumstances on which any forward-looking statement is based.
|
Item
7.01
|
Regulation
FD Disclosure.
|
On
August 6, 2020, the Company issued a press release announcing the Company’s financial results for its second quarter ended
June 30, 2020. In addition, the Company will be using a slide presentation during its earnings conference call. The information
included in this Item 7.01 and in Exhibits 99.1 and 99.2 shall not be deemed “filed” for purposes of Section 18
of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference
in any filing under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
|
Item
9.01
|
Financial
Statements and Exhibits.
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: August 6, 2020
|
THERAPEUTICSMD, INC.
|
|
|
|
By:
|
/s/ James C. D'Arecca
|
|
Name:
|
James C. D'Arecca
|
|
Title:
|
Chief Financial Officer
|
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Apr 2024 to May 2024
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From May 2023 to May 2024